All In Biotech

Drug Trial Radar · NCT07310095

A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Sep 15, 2027

Study completion Nov 15, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.

Conditions

  • Crohn Disease

Interventions

  • Guselkumab (GUS)Drug

    Guselkumab will be administered intravenously or by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Remission At Week 48Time frame: At Week 48

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, China · Recruiting

  • The Sixth Affiliated Hospital Sun Yat sen University

    Guangzhou, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Ruijin Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.